Look up one drug

Matched class: 68:20:06 Incretin Mimetics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 68:20:06 Incretin Mimetics

SEMAGLUTIDE

· 13 products · Limited Use, codes 667 (2), Limited Use, codes 666 (2), Limited Use, codes 665 (3), Limited Use, codes 738 (1), Limited Use, codes 662 (1), Limited Use, codes 739 (1), Limited Use, codes 663 (1), Limited Use, codes 740 (1), Limited Use, codes 664 (1) · strengths: 0.68mg/mL, 1.34mg/mL, 1.5mg, 3mg, 4mg, 7mg, 9mg, 14mg · Inj Sol - Pref Pen 3mL Pk, Inj Sol-Pref Pen 1.5mL Pk, Inj Sol-Pref Pen 3mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:06

Matched class: 68:20:14 Insulins (Long Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN DEGLUDEC, INSULIN DETEMIR 68:20:14 Insulins (Long Acting)

INSULIN DEGLUDEC

· 3 products · General benefit · strengths: 100U/mL, 200U/mL · Inj Sol-3X5mL Cart Pk, Inj Sol-Flextouch Pref Pen 3x3mL Pk, Inj Sol-Flextouch Pref Pen 5x3mL Pk

INSULIN DETEMIR

· 2 products · General benefit · strengths: 100U/mL · Inj Sol-5x3mL Pk, Inj Sol-Pref Disp Pen 5X3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:14

1 INDICATIONS LANTUS [insulin glargine injection (rDNA origin)] is a recombinant human insulin analog indicated for once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. LANTUS is also indicated in the treatment of pediatric patients (˃6 years old) with Type 1 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia . 1.1 Pediatrics Pediatrics (>6 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LANTUS in pediatric patients over 6 years of age with Type 1 diabetes mellitus has been established. Therefore, Health Canada has authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. https://pdf.hres.ca/dpd_pm/00063800.PDF PM date: December 1, 2021 Source product: LANTUS; DIN 02245689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1. Indications SOLIQUA, a fixed ratio combination of insulin glargine and lixisenatide, once daily injection, is indicated in combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on: • basal insulin (less than 60 units daily) alone or in combination with metformin • a glucagon-like peptide-1 receptor agonist (GLP-1RA) in combination with metformin Use alternative antidiabetic products if patients require basal insulin below 15 units or over 60 units. See 4 Dosage and Administration Therapy with basal insulin or a GLP-1RA should be discontinued prior to initiation of SOLIQUA, since SOLIQUA contains both basal insulin and a GLP-1RA (lixisenatide). Limitations of Use • SOLIQUA has not been studied with short acting insulin. • SOLIQUA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. • SOLIQUA is not recommended for use in combination with any other product containing lixisenatide or another GLP-1RA. • SOLIQUA has not been studied in patients with a history of pancreatitis. Co… https://pdf.hres.ca/dpd_pm/00082751.PDF PM date: 2025-12-11 Source product: SOLIQUA; DIN 02478293; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.